DiaSorin stock: Equita raises target from EUR 72.00 to EUR 90.00 for DiaSorin stock

Published on 10/21/2026 at 17:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Equita expects EUR 308.00 million third-quarter revenue in 2026. DiaSorin stock costs EUR 78.19 on October 21, 2026 at 5:35 p.m. CEST.

Equita target and reporting date

Equita raised its DiaSorin target from EUR 72.00 to EUR 90.00 and changed its rating to Buy on October 21, 2026.
Equita expects third-quarter 2026 revenue of EUR 308.00 million, up 10.20 percent year over year.
DiaSorin stock costs EUR 78.19 at Lang & Schwarz on October 21, 2026 at 5:35 p.m. CEST, 5.00 percent below its 52-week high.
DiaSorin is due to report third-quarter results on November 12, 2026.

Techniker im Reinraum bedienen automatisierte Diagnostikgeräte in modernem Biotech-Labor — Modernes Diagnostiklabor von DiaSorin S.p.A., ISIN IT0003497168, zeigt präzise Biotech-Produktion und klinische Fertigung, Illustration mit AI erstellt.

DiaSorin stock (ISIN IT0003492391) has a new EUR 90.00 price target from Equita, which raised its view from EUR 72.00 and changed its rating from Hold to Buy on October 21, 2026, according to Teleborsa. The EUR 90.00 target is 15.11 percent above the EUR 78.19 Lang & Schwarz price on October 21, 2026 at 5:35 p.m. CEST.

Revenue expectations move higher

Equita expects DiaSorin to post third-quarter 2026 revenue of EUR 308.00 million, an increase of 10.20 percent from the same period in 2025. The estimate includes 7.60 percent organic growth and 2.60 percent currency support, according to Milano Finanza. The same report said second-quarter revenue reached EUR 315.00 million, up 2.90 percent year over year.

Stock stays below its yearly high

DiaSorin's EUR 78.19 price sits within a 52-week range of EUR 52.34 to EUR 82.30 as of October 21, 2026. It is 5.00 percent below the upper end of that range. Trading volume stood at 378,468 shares at 3:22 p.m. CEST, while the price-to-earnings ratio was 24.50.

Results date and valuation

DiaSorin is scheduled to publish third-quarter 2026 results on November 12, 2026, as reported by Borsa Italiana. DiaSorin's market capitalization was EUR 3.9 billion on October 21, 2026, and its price-to-earnings ratio was 24.50. The scheduled report gives investors a near-term test of whether the expected third-quarter acceleration can support the higher target.

What does the target imply?

Equita's EUR 90.00 target implies 15.11 percent upside from the Lang & Schwarz price, while its revised third-quarter revenue estimate points to a sharper comparison with the EUR 315.00 million reported for the second quarter. The figures describe separate reference points: one is an analyst valuation, and the other is an operating forecast.

Price and reporting date

DiaSorin stock was trading at EUR 78.19 at Lang & Schwarz on October 21, 2026 at 5:35 p.m. CEST. The 52-week high was EUR 82.30 on the same market-data date, leaving the stock 5.00 percent below that level. The further course of trading is shown by the continuously updated real-time quote of DiaSorin stock.